Lupus Awareness Month takes place during October in the UK every year. It is an important opportunity to raise awareness of the disease amongst the public and medical profession as well as improving the understanding of the impact that lupus can have.
By making people more aware of lupus you can help control its impact.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.